Interventional, Exploratory, Open-label Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Lu AF28996 in Japanese Men and Women With Parkinson's Disease
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Lu AF28996 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lundbeck A/S
- 06 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2023 Status changed from not yet recruiting to recruiting.
- 24 Aug 2023 New trial record